The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Rodríguez-Abreu D, Cobo M, García-Román S, Viteri-Ramírez S, Jordana-Ariza N, García-Peláez B, Reguart N, Aguilar A, Codony-Servat J, Drozdowskyj A, Molina-Vila MA, d'Hondt E, Rosell R.
Rodríguez-Abreu D, et al.
Lung Cancer. 2022 Feb;164:8-13. doi: 10.1016/j.lungcan.2021.12.014. Epub 2021 Dec 23.
Lung Cancer. 2022.
PMID: 34971901
Clinical Trial.